CHRS|Coherus Oncology, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $42M
- ▲ 60% YoY
- Operating margin
- -429.5%
- ▲ 43% YoY
- EBITDA
- −$180M
- ▲ 9.2% YoY
- Market cap
- $128M
- Employees
- 100,000
- $422 revenue each
- Net debt / EBITDA
- —
- −$9M net debt
- AI in 10-K
- 0.0
- mentions per 10K words
TSR below peersNo
—
3+ of last 5 years
High CEO pay despite TSRNo
$5M median
Median CEO pay ≥ $15M while TSR trails
Earnings not backed by cashYes
-82% of net income
Cash flow under 80% of net income
Dilutive SBCYes
40% of revenue
Over 10% of revenue
Payouts exceed cash flowNo
-0% of cash flow
Buybacks + dividends over cash flow
Goodwill-heavyNo
0% of assets
Over 40% of assets
Shareholder dissentNo
87% lowest support
Any vote under 80% support
Buyer economics 2 of 4
Low revenue per employeeYes
$422 · 8th pct
Bottom quartile of its SIC industry
Quiet on AIYes
0.0 per 10K words · 0th pct
Bottom quartile of AI mentions in 10-Ks
Net cashNo
—
More cash than debt, positive EBITDA
Buyout-sizedNo
$128M market cap
Market cap $500M–$5B
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY | Trend |
|---|
| Revenue | $327M | $211M | $1M | $26M | $42M | ▲ 60% | |
|---|
| Operating income | −$264M | −$257M | −$216M | −$200M | −$181M | ▲ 9.3% | |
|---|
| Net income | −$287M | −$292M | −$238M | $29M | $168M | ▲ 489% | |
|---|
| Operating cash flow | −$37M | −$241M | −$175M | −$20M | −$139M | ▼ 578% | |
|---|
| Capex | $1M | $2M | $286K | — | — | | |
|---|
| Stock-based comp | $51M | $51M | $43M | $28M | $17M | ▼ 39% | |
|---|
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|
| Dec 2, 2019 | KKR Fund Holdings L.P. | SC 13D/A | 5.6% | Passive |
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|
| FY2025 | $3M | $3M | 18 | — |
| FY2024 | $5M | $2M | 17 | — |
| FY2023 | $6M | $2M | 42 | — |